The inhibition of lipogenesis-related genes, specifically FAS and SREBP-1c, which are crucial components in the pathogenesis of NAFLD, has been demonstrated by P-AMPK (51). The gene discussed is FAS; the disease is metabolic dysfunction-associated steatotic liver disease.